^Danysz W, Plaznik A, Kostowski W, Malatynska E, Järbe TU, Hiltunen AJ, Archer T. „Comparison of desipramine, amitriptyline, zimeldine and alaproclate in six animal models used to investigate antidepressant drugs”.Pharmacology & Toxicology.62 (1): 42—50.PMID2965810.
^Jäkälä P, Sirviö J, Riekkinen P, Valjakka A, Riekkinen P (1992). „The effects of alaproclate and p-chlorophenylalanine on cued navigation performance in rats”.Journal of Neural Transmission. Parkinson's Disease and Dementia Section.4 (1): 43—52.PMID1531758.
^A Wilkinson; M Courtney; A Westlind-Danielsson; G Hallnemo; K E Akerman (1994). „Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow”.JPET.271 (3): 1314—1319.
^K L Nicholson & R L Balster (23. 04. 2003). „Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats”.Psychopharmacology.